AzTrials
AzTrials

Colorectal CancerCTLm-CCPNCT06780423

Structural Characteristics of Trunk and Limb Muscles in Cachectic Colorectal Cancer Patients

An observational study of Colorectal Cancer and Cancer Cachexia, run by Hasselt University at 2 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Until now, cancer is still associated with high morbidity and mortality, and is therefore a big issue for the public health. Colorectal cancer is the second leading cause of cancer death in developed countries. In advanced colorectal cancer, 60% of these patients develop cachexia. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Colorectal Cancer, Cancer Cachexia
What is being tested?
Minimal invasive fine needle muscle biopsies
Type of treatment
Surgery or procedure
How many people
60 participants
Where
2 sitesBelgium
Study dates
23 Jan 2022to 10 Sep 2025
How long will I take part?
2 Days
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 12 cachectic colorectal cancer patients, 25 non-cachectic colorectal cancer patients, and 25 healthy controls will be recruited in the study. Colorectal cancer patients will be recruited by the surgeans from the Jessa Hospital (Hasselt, Belgium), and the healthy controls will be recruited by the local researcher from Hasselt University.

Who may be able to join

  • minimum age of 18 years old
  • unwanted weight loss > 5% in the last 6 months OR > 2% unwanted weight loss in combination with a BMI < 20kg/m2 OR >2% unwanted weight loss in combination with sarcopenia
  • Cachexia staging score (CSS): 5-12
  • minimum age of 18 years old
  • No unwanted weight loss > 5% in the last 6 months OR > 2% unwanted weight loss in combination with a BMI < 20kg/m2 OR >2% unwanted weight loss in combination with sarcopenia
  • Cachexia staging score (CSS): 0-2
  • minimum age of 18 years old

Who cannot join

  • Mental of psychological condition
  • Insufficient knowledge of the Dutch language
  • Muscle diseases affecting the spine and lower limbs
  • Bedridden
  • Non-Cachectic cancer patients.
  • Mental of psychological condition
Show all 14Show fewer
  • Insufficient knowledge of the Dutch language
  • Muscle diseases affecting the spine and lower limbs
  • Bedridden
  • Healthy controls.
  • Mental of psychological condition
  • Insufficient knowledge of the Dutch language
  • Muscle diseases affecting the spine and lower limbs
  • Bedridden

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Britt van de Haterd, PhD student contact

0032479871509

britt.vandehaterd@uhasselt.be

Kenneth Verboven, Professor contact

kenneth.verboven@uhasselt.be

Belgium2 sites, 2 recruiting
  • Hasselt University - REVAL research institution

    Diepenbeek, Limburg, 3520

    Kenneth Verboven, Professor, +3211269315, kenneth.verboven@uhasselt.be

    Britt van de Haterd, PhD student, 0032479871509, britt.vandehaterd@uhasselt.be

    Recruiting
  • Jessa Hospital

    Hasselt, Limburg, 3500

    Bert Houben, Doctor, +3211 33 75 19, bert.houben@jessazh.be

    Recruiting

Other trials in Belgium

About this study

Until now, cancer is still associated with high morbidity and mortality, and is therefore a big issue for the public health. Colorectal cancer is the second leading cause of cancer death in developed countries. In advanced colorectal cancer, 60% of these patients develop cachexia. The presence of cachexia plays an important role in the high mortality rate of cancer. Cachexia is characterized by involuntary weight loss with loss of skeletal muscle with or without loss of fat mass.

The aim of this study is to determine the feasibility of taking muscle biopsies of cachectic colorectal cancer patients. Skeletal muscle characteristics will be compared between biopsies of the m. erector spinae and the m. vastus lateralis from cachectic colorectal cancer patients, non-cachectic colorectal cancer patients and healthy controls.

Read more

10 cachectic, 25 non-cachectic, and 25 healthy controls will be recruited for this study. It is an observational study, so measurements will be taken at one time point. Interventions/measurements:

  • muscle biopsies
  • blood samples
  • 3D freehand ultrasound
  • Short physical performance battery test
  • handgrip strength
  • questionnaires (activity pattern, quality of life)
Being tested
Minimal invasive fine needle muscle biopsies
Keywords
colorectal cancer, cachexia, skeletal muscle, skeletal muscle fibers, capillarization
Medical subject headings
Colorectal Neoplasms, Cachexia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Minimal invasive fine needle muscle biopsiesProcedure or surgery

    Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.

Study groups in NCT06780423
Study groupRoleWhat they receive
Cachectic colorectal cancer patientsNot described
Receives: Procedure: Minimal invasive fine needle muscle biopsies
Non-cachectic colorectal cancer patientsNot described
Receives: Procedure: Minimal invasive fine needle muscle biopsies
Healthy controlsNot described
Receives: Procedure: Minimal invasive fine needle muscle biopsies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Skeletal muscle fiber typing

    Immunofluorescence staining of skeletal muscle biopsies to observe different muscle fiber types (myosin heavy chains)

    Measured: at enrollment

  2. skeletal muscle nuclei

    Immunofluorescence staining with DAPI

    Measured: at enrollment

  3. Inflammatory parameters

    ELISA (bloodsamples), immunofluorescence staining (muscle biopsies)

    Measured: at enrollment

  4. Mitochondrial morphology

    mitochondrial fusion and fission (western blot) mitochondrial OXPHOS (western blot)

    Measured: at enrollment

Secondary outcomes (8)
  1. 3D freehand ultrasound

    measuring the volume of the m. rectus femoris

    Measured: at enrollment

  2. CT-scans

    level lumbar 3 To calculate the cross-sectional area of the m. erector spinae.

    Measured: at enrollment

  3. Activity pattern

    PASIPD questionnaire

    Measured: at enrollment

  4. VAS score

    to descripe the pain at the moment of the biopsy procedure. Score range is 0 to 10. With 0 no pain until 10 the worst pain.

    Measured: at enrollment

  5. Handgrip strength

    Using the JAMAR to measure the handgripstrength

    Measured: at enrollment

  6. Short Physical Performance Battery (SPPB) test

    Including a balance test, sit-to-stand test and four meter walking test

    Measured: at enrollment

  7. Quality of Life questionnaire

    SF-36 questionnaire

    36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

    Measured: at enrollment

  8. skeletal muscle capillarization

    Immunofluorescence staining for capillaries in the skeletel muscle biopsies.

    Measured: at enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2025
  2. Study start23 Jan 2022
  3. Primary completion15 Mar 2025
  4. Study completion10 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
60 participants (estimated)
Target duration
2 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT06780423
Sponsor's protocol ID
2021/148 - CTLm-CCP
Acronym
CTLm-CCP
Status last verified
Sep 2025
First submitted
13 Jan 2025
Last updated
9 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Cancer and Cancer Cachexia, run by Hasselt University at 2 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Britt van de Haterd, PhD student (0032479871509, britt.vandehaterd@uhasselt.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Skeletal muscle fiber typing (time frame: at enrollment). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in